trial · primary record
Cyclophosphamide
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 349 |
| Primary completion | 2026-12-31 |
| Primary endpoint | 3-year Progression-free Survival Rate |
| Registry ID | NCT01856192 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:17.746Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01856192
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.